Page 116 - 中国全科医学2022-14

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·1777·

executive committee，June 2001［J］. Am J Respir Crit Care Med， male with fever and persistent lung infiltrate［J］. Respir Care，
2002，165（2）：277-304. DOI：10.1164/ajrccm.165.2.ats01. 2009，54（9）：1263-1265.
［3］TRAVIS W D，COSTABEL U，HANSELL D M，et al. An official ［17］FEKRAZAD M H，EBERHARDT S，JONES D V，et al.
American Thoracic Society/European Respiratory Society statement： Development of bronchiolitis obliterans organizing pneumonia with
update of the international multidisciplinary classification of the platinum-based chemotherapy for metastatic rectal cancer［J］.
idiopathic interstitial pneumonias［J］. Am J Respir Crit Care Med， Clin Colorectal Cancer，2010，9（3）：177-178. DOI：
2013，188（6）：733-748. DOI：10.1164/rccm.201308-1483ST. 10.3816/CCC.2010.n.024.
［4］COTTIN V，CORDIER J F. Cryptogenic organizing pneumonia［J］. ［18］BELLANGER C，DHOOGE M，TABOURET T，et al. Incidence
Semin Respir Crit Care Med，2012，33（5）：462-475. DOI： of organizing pneumonia induced by oxaliplatin chemotherapy for
10.1055/s-0032-1325157. digestive cancer［J］. Ann Pharmacother，2015，49（4）：494-
［5］MOESER A，PLETZ M W，HAGEL S，et al. Lung disease and 495. DOI：10.1177/1060028015569595.
ulcerative colitis——mesalazine-induced bronchiolitis obliterans with ［19］MICHIELIN O，UDRY E，PÉRIARD D，et al. Irinotecan-induced
organizing pneumonia or pulmonary manifestation of inflammatory interstitial pneumonia［J］. Lancet Oncol，2004，5（5）：322-
bowel disease?［J］. Zeitschrift Fur Gastroenterol，2015，53（9）： 324. DOI：10.1016/S1470-2045（04）01471-8.
1091-1098. DOI：10.1055/s-0041-103377. ［20］LEE Y J，KIM J H，KIM S W，et al. A case of organizing
［6］GHANDOURAH H，BHANDAL S，BRUNDLER M A， pneumonia associated with FOLFIRI chemotherapy［J］. Tuberc
et al. Bronchiolitis obliterans organising pneumonia associated Respir Dis （Seoul），2014，77（6）：262-265. DOI：
with anticonvulsant hypersensitivity syndrome induced by 10.4046/trd.2014.77.6.262.
lamotrigine［J］. BMJ Case Rep，2016：bcr2014207182. DOI： ［21］DASARI S，TCHOUNWOU P B. Cisplatin in cancer therapy：
10.1136/bcr-2014-207182. molecular mechanisms of action［J］. Eur J Pharmacol，2014，
［7］TERBUCH A，TIU C，CANDILEJO I M，et al. Radiological 740：364-378. DOI：10.1016/j.ejphar.2014.07.025.
patterns of drug-induced interstitial lung disease （DILD） in early- ［22］VANDEIX E，FAVARD F，PICHON N，et al. Bortezomib-
phase oncology clinical trials［J］. Clin Cancer Res，2020，26（18）： induced bronchiolitis obliterans organizing pneumonia［J］. Case
4805-4813. DOI：10.1158/1078-0432.CCR-20-0454. Rep Pulmonol，2012，2012：1-3. DOI：10.1155/2012/430141.
［8］GUPTA A，SEN S，NAINA H. Acute fibrinous and organising ［23］NISHINO M，BOSWELL E N，HATABU H，et al. Drug-related
pneumonia：a rare histopathological variant of chemotherapy-induced pneumonitis during mammalian target of rapamycin inhibitor
lung injury［J］. BMJ Case Rep，2016，2016：bcr2016214721. therapy：radiographic pattern-based approach in waldenström
DOI：10.1136/bcr-2016-214721. macroglobulinemia as a paradigm［J］. Oncologist，2015，20（9）：
［9］MOORE B B，HOGABOAM C M. Murine models of pulmonary 1077-1083. DOI：10.1634/theoncologist.2015-0033.
fibrosis［J］. Am J Physiol Lung Cell Mol Physiol，2008，294（2）： ［24］FEHRENBACH U，RODRÍGUEZ-LAVAL V，JANN H，et al.
L152-160. DOI：10.1152/ajplung.00313.2007. Everolimus-induced pneumonitis in neuroendocrine neoplasms：
［10］HECHT S M. Bleomycin：new perspectives on the mechanism correlation of CT findings and clinical signs［J］. Acta Radiol，
of action［J］. J Nat Prod，2000，63（1）：158-168. DOI： 2021，62（8）：1006-1015. DOI：10.1177/0284185120950100.
10.1021/np990549f. ［25］NAZER L，ALNAJJAR T，SALAH S，et al. Fatal case of
［11］BOLZÁN A D，BIANCHI M S. DNA and chromosome damage cryptogenic organizing pneumonia associated with everolimus［J］.
induced by bleomycin in mammalian cells：an update［J］. Ann Saudi Med，2014，34（5）：437-439. DOI：10.5144/0256-
Mutat Res Rev Mutat Res，2018，775：51-62. DOI：10.1016/j. 4947.2014.437.
mrrev.2018.02.003. ［26］KIM C J，MCKENZIE D，JOSEPH J K，et al. Refractory
［12］HAY J，SHAHZEIDI S，LAURENT G. Mechanisms of bleomycin- metastatic insulinoma treated with everolimus，complicated by
induced lung damage［J］. Arch Toxicol，1991，65（2）：81- cryptogenic organizing pneumonia［J］. Am J Med Case Rep，
94. DOI：10.1007/BF02034932. 2019，7（7）：125-132. DOI：10.12691/ajmcr-7-7-2.
［13］SEKHRI A，PALANISWAMY C，KURMAYAGARI K，et al. ［27］FRIJA J，JOLY D，KNEBELMANN B，et al. Everolimus-related
Interstitial lung disease associated with azacitidine use：a case organizing pneumonia：a report establishing causality［J］. Invest
report［J］. Am J Ther，2012，19（2）：e98-100. DOI： New Drugs，2012，30（3）：1244-1247. DOI：10.1007/s10637-
10.1097/mjt.0b013e3181e7a526. 010-9624-y.
［14］ADAMS C D，SZUMITA P M，BAROLETTI S A，et al. ［28］ALGHULAYQAH A，ALSHAMSAN B，BAZARBASHI S，et al.
Azacitidine-induced interstitial and alveolar fibrosis in a patient with Organizing pneumonia secondary to cetuximab in a patient with colorectal
myelodysplastic syndrome［J］. Pharmacotherapy，2005，25（5）： cancer［J］. Arch Monaldi Le Malattie Del Torace，2019，89（3）.
765-768. DOI：10.1592/phco.25.5.765.63579. DOI：10.4081/monaldi.2019.1074.
［15］ALNIMER Y，SALAH S，ABUQAYAS B，et al. Azacitidine- ［29］HARDING J，BURTNESS B. Cetuximab：an epidermal growth
induced cryptogenic organizing pneumonia：a case report and review factor receptor chemeric human-murine monoclonal antibody［J］.
of the literature［J］. J Med Case Rep，2016，10：15. DOI： Drugs Today （Barc），2005，41（2）：107-127. DOI：
10.1186/s13256-016-0803-0. 10.1358/dot.2005.41.2.882662.
［16］VASU T S，CAVALLAZZI R，HIRANI A，et al. A 64-year-old ［30］KOSHIKAWA K，TERADA J，ABE M，et al. Clinical